** Shares of drugmaker Y-mAbs Therapeutics YMAB.O fall 8.5% to $4.75, hitting a near two-year low
** Company forecasts 2025 total revenue to be between $75 million and $90 million, below analysts' estimates of $104.54 million, according to data compiled by LSEG
** YMAB reports Q4 total revenue of $26.5 million, below analysts' estimates of $27.29 million
** In the past 12 months, YMAB has fallen 70%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.